Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 7/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 7/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12973274 | 0.87 | KCNH2 (0.52) | KCNH2SCN3AALOX5S1PR5S1PR1 | |
| SCHEMBL20835720 | 0.80 | FFAR2 (0.42) | KCNH2 | |
| SCHEMBL2713220 | 0.77 | KCNH2 (0.55) | KCNH2S1PR5 | |
| SCHEMBL2714652 | 0.77 | KCNH2 (0.55) | KCNH2S1PR5 | |
| SCHEMBL2712695 | 0.77 | KCNH2 (0.55) | KCNH2S1PR5 | |
| SCHEMBL2839895 | 0.75 | KCNH2 (0.50) | KCNH2SCN3ASCN9A | |
| SCHEMBL4759457 | 0.75 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL2714031 | 0.75 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL2712967 | 0.75 | KCNH2 (0.39) | KCNH2 | |
| SCHEMBL2713204 | 0.75 | KCNH2 (0.39) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855218-B2 | (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels | Convergence Pharmaceuticals Limited (GB) | 2010-12-21 | — | — | US | disclosed |
| EP-1943216-B1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LTD (GB) | 2010-06-30 | — | — | EP | disclosed |
| US-20080306122-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306122-A1 | Novel Compounds | CYP11B1, CYP11B2, CYP46A1 | KCNH2 3313/4885SCN3A 2352/4885ALOX5 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.